Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

NCT01129349 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01129349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01129349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2010
Completion date
March 31, 2013
Enrollment
44 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors